The potential cost savings offered by biosimilars may never be realized in the United States if reimbursement incentives are not implemented to ensure their adoption and long-term use, according to industry expert Molly Burich.
The potential cost savings offered by biosimilars may never be realized in the United States if reimbursement incentives are not implemented to ensure their adoption and long-term use. According to Molly Burich, associate director of public policy, Biosimilars, Pipeline and Reimbursement, Boehringer Ingelheim, 2 of the biggest challenges concern the inconsistent policies on biosimilars that have been implemented by CMS and the Medicare Part D “donut hole” coverage gap.
Estimates of the potential savings that could be realized from widespread adoption of biosimilars vary from 20% to 40%; at the higher end of the range, those percentages suggest a savings of $66 billion by 2024. Burich argues that it is critical to ensure that the current reimbursement systems are appropriately structured to drive biosimilar uptake.
Citing inconsistency within the CMS rules, Burich says, “Unfortunately, at the federal level, the CMS has implemented a series of inconsistent policies on biosimilars that may impact their uptake and savings potential.” All biosimilars for the same reference product are assigned 1 billing and payment code (called a J-code) by CMS and are reimbursed at a blended rate; this approach treats biosimilars as generic products, and assumes that they are equivalent to one another. However, CMS’ policy for Medicaid pricing takes the opposite approach: biosimilars will be considered branded products, and manufacturers will be required to pay the 23.1% rebate for branded products as mandated by the Affordable Care Act (ACA).
With respect to the Medicare Part D coverage gap, the so-called “donut hole” coverage gap for patients on Medicare Part D begins after the patient hits $3700 in drug spending in 2017. Once the patient spends $4950, she will leave the coverage gap, and her out-of-pocket drug cost will be significantly reduced for the rest of the year. Through the ACA’s mandated Coverage Gap Discount Program (CGDP), manufacturers must pay a 50% rebate for all branded drugs subject to the coverage gap. The CGDP excludes both generic and biosimilar drugs from being discounted, however. Burich says that the exclusion of biosimilars from the CGDP program means 2 things for patients: first, patients will have higher cost-sharing for biosimilars, and second, they will remain in the donut hole for longer periods.
During the time that a patient is subject to the coverage gap, the 50% manufacturer’s rebate on branded drugs counts toward the patient’s true out-of-pocket (OOP) costs, a situation that moves the patient through the coverage gap faster. Being excluded from the CGDP, any discount offered on biosimilars under the plan would not count toward the patient’s true OOP costs; therefore, the patient would experience both a higher cost share and a longer gap in coverage than if she were using a branded drug.
The coverage gap will close for patients in 2020, when patients will begin to pay 25% of the cost of branded or generic/biosimilar drugs once they reach the coverage gap. But the impact on the true OOP costs will still force patients to remain in the coverage gap for longer periods if they take biosimilars.
Burich believes that the exclusion of biosimilars from the CGDP means that costs to the plan will be higher through 2020 and beyond. The plan’s reimbursement responsibility for a brand product in the coverage gap will be 25%, while its responsibility for a generic product will be 75%. “The result of this policy makes it potentially very unlikely for a Part D sponsor to push the use of biosimilars under Medicare Part D,” Burich explains. It is also unlikely that Part D sponsors will expend much effort on the matter as long as patient and Part D plan financial disincentives exist.
What are potential solutions? Burich cites an analysis by Avalere Health that proposed 2 potential actions: first, allowing biosimilars to participate in the CGDP and pay the 50% rebate, and second, allowing CMS to create a new biosimilar tier to give Part D plans flexibility on how they manage biosimilars. Both approaches would require legislative action. The first is a more likely and timely solution, according to Burich, because it could be used for biosimilars that have been approved but that are not yet marketed under Medicare Part D.
CMS is positioned to play a pivotal role in the development of policies, Burich states, that will allow biosimilars to realize their full potential in the United States. “Addressing the coverage gap in Part D is a critical place to start.”
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.